Fiera Capital Corp Decreases Position in AstraZeneca PLC (NASDAQ:AZN)
Fiera Capital Corp trimmed its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 5.9% during the third quarter, according to the company in its most recent filing with the Securities and ...
ETF Daily News8h
AstraZeneca’s (AZN) Buy Rating Reaffirmed at Shore Capital
Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and ...
Buy, Sell, or Hold AstraZeneca Stock? Key Tips Ahead of Q3 Earnings
AstraZeneca's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected ...
AstraZeneca says experimental obesity pill ‘competitive,’ Bloomberg reports
AstraZeneca (AZN) said Monday at the ObesityWeek conference in San Antonio, Texas that its experimental obesity pill was well-tolerated by ...
lifesciencesweden.se6d
AZ gets approval for drug targeting rare disease –it may reduce cortisone dependence
AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.